Physician profile
Vineet Venugopal
NPI 1124211560
$8,264.40
in general payments reported to CMS, 2019-2025
41 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $761 · 2021: $714 · 2022: $1,475 · 2023: $1,150 · 2024: $1,230 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,905 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,904.94 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,074.05 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $804.75 | 2019-2025 | |
| Pfizer INC. | $724.14 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $716.15 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $707.54 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $553.18 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $468.37 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.83 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $337.32 | 2021-2025 | |
| Novo Nordisk INC | $313.00 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $284.93 | 2019-2024 | Xarelto |
| Cvrx, INC. | $269.19 | 2022 | |
| Abbott Laboratories | $160.78 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Actelion Pharmaceuticals US, INC. | $137.60 | 2022-2023 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.14 | 2019-2025 | Lifevest |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $126.49 | 2019-2022 | |
| Gilead Sciences, INC. | $123.73 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $99.98 | 2023-2024 | Inpefa |
| Lilly USA, LLC | $96.90 | 2019-2025 | Zepbound, Mounjaro |
| Arbor Pharmaceuticals, INC. | $86.38 | 2019-2021 | |
| Medtronic, INC. | $84.94 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $83.17 | 2019 | |
| Abiomed | $81.08 | 2024-2025 | Impella |
| Esperion Therapeutics, INC. | $79.13 | 2024-2025 | Nexletol |
| Atricure, INC. | $76.91 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Sanofi-Aventis U.S. LLC | $62.79 | 2019 | |
| Heartflow, INC. | $46.09 | 2024 | |
| Kestra Medical Technology Services, INC. | $28.37 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $23.98 | 2025 | Attruby |
| Itamar Medical INC | $21.40 | 2023 | Watchpatone |
| Glaxosmithkline, LLC. | $19.97 | 2023 | Shingrix |
| Biohaven Pharmaceuticals, INC. | $17.43 | 2021 | |
| Irhythm Technologies, INC. | $17.25 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.73 | 2023 | Edarbi |
| Lupin INC. | $11.78 | 2020 | |
| Chiesi USA, INC. | $10.93 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineet Venugopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.